Emma Deas
UCL Institute of Neurology
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Emma Deas.
Molecular Cell | 2009
Sonia Gandhi; Alison Wood-Kaczmar; Zhi Yao; Helene Plun-Favreau; Emma Deas; Kristina Klupsch; Julian Downward; David S. Latchman; Sarah J. Tabrizi; Nicholas W. Wood; Michael R. Duchen; Andrey Y. Abramov
Summary Mutations in PINK1 cause autosomal recessive Parkinsons disease. PINK1 is a mitochondrial kinase of unknown function. We investigated calcium homeostasis and mitochondrial function in PINK1-deficient mammalian neurons. We demonstrate physiologically that PINK1 regulates calcium efflux from the mitochondria via the mitochondrial Na+/Ca2+ exchanger. PINK1 deficiency causes mitochondrial accumulation of calcium, resulting in mitochondrial calcium overload. We show that calcium overload stimulates reactive oxygen species (ROS) production via NADPH oxidase. ROS production inhibits the glucose transporter, reducing substrate delivery and causing impaired respiration. We demonstrate that impaired respiration may be restored by provision of mitochondrial complex I and II substrates. Taken together, reduced mitochondrial calcium capacity and increased ROS lower the threshold of opening of the mitochondrial permeability transition pore (mPTP) such that physiological calcium stimuli become sufficient to induce mPTP opening in PINK1-deficient cells. Our findings propose a mechanism by which PINK1 dysfunction renders neurons vulnerable to cell death.
Nature Cell Biology | 2007
Helene Plun-Favreau; Kristina Klupsch; Nicoleta Moisoi; Sonia Gandhi; Svend Kjær; David Frith; Kirsten Harvey; Emma Deas; Robert J. Harvey; Neil Q. McDonald; Nicholas W. Wood; L. Miguel Martins; Julian Downward
In mice, targeted deletion of the serine protease HtrA2 (also known as Omi) causes mitochondrial dysfunction leading to a neurodegenerative disorder with parkinsonian features. In humans, point mutations in HtrA2 are a susceptibility factor for Parkinsons disease (PARK13 locus). Mutations in PINK1, a putative mitochondrial protein kinase, are associated with the PARK6 autosomal recessive locus for susceptibility to early-onset Parkinsons disease. Here we determine that HtrA2 interacts with PINK1 and that both are components of the same stress-sensing pathway. HtrA2 is phosphorylated on activation of the p38 pathway, occurring in a PINK1-dependent manner at a residue adjacent to a position found mutated in patients with Parkinsons disease. HtrA2 phosphorylation is decreased in brains of patients with Parkinsons disease carrying mutations in PINK1. We suggest that PINK1-dependent phosphorylation of HtrA2 might modulate its proteolytic activity, thereby contributing to an increased resistance of cells to mitochondrial stress.
Brain | 2009
Juliane Neumann; Jose Bras; Emma Deas; Sean S. O'Sullivan; Laura Parkkinen; Robin H. Lachmann; Abi Li; Janice L. Holton; Rita Guerreiro; Reema Paudel; Badmavady Segarane; Andrew Singleton; Andrew J. Lees; John Hardy; Henry Houlden; Tamas Revesz; Nicholas W. Wood
Mutations in the glucocerebrosidase gene (GBA) are associated with Gauchers disease, the most common lysosomal storage disorder. Parkinsonism is an established feature of Gauchers disease and an increased frequency of mutations in GBA has been reported in several different ethnic series with sporadic Parkinsons disease. In this study, we evaluated the frequency of GBA mutations in British patients affected by Parkinsons disease. We utilized the DNA of 790 patients and 257 controls, matched for age and ethnicity, to screen for mutations within the GBA gene. Clinical data on all identified GBA mutation carriers was reviewed and analysed. Additionally, in all cases where brain material was available, a neuropathological evaluation was performed and compared to sporadic Parkinsons disease without GBA mutations. The frequency of GBA mutations among the British patients (33/790 = 4.18%) was significantly higher (P = 0.01; odds ratio = 3.7; 95% confidence interval = 1.12-12.14) when compared to the control group (3/257 = 1.17%). Fourteen different GBA mutations were identified, including three previously undescribed mutations, K7E, D443N and G193E. Pathological examination revealed widespread and abundant alpha-synuclein pathology in all 17 GBA mutation carriers, which were graded as Braak stage of 5-6, and had McKeiths limbic or diffuse neocortical Lewy body-type pathology. Diffuse neocortical Lewy body-type pathology tended to occur more frequently in the group with GBA mutations compared to matched Parkinsons disease controls. Clinical features comprised an early onset of the disease, the presence of hallucinations in 45% (14/31) and symptoms of cognitive decline or dementia in 48% (15/31) of patients. This study demonstrates that GBA mutations are found in British subjects at a higher frequency than any other known Parkinsons disease gene. This is the largest study to date on a non-Jewish patient sample with a detailed genotype/phenotype/pathological analyses which strengthens the hypothesis that GBA mutations represent a significant risk factor for the development of Parkinsons disease and suggest that to date, this is the most common genetic factor identified for the disease.
Cell | 2012
Nunilo Cremades; Samuel I. A. Cohen; Emma Deas; Andrey Y. Abramov; Allen Yuyin Chen; Angel Orte; Massimo Sandal; Richard W. Clarke; Paul D. Dunne; Francesco A. Aprile; Carlos W. Bertoncini; Nicholas W. Wood; Tuomas P. J. Knowles; Christopher M. Dobson; David Klenerman
Summary Here, we use single-molecule techniques to study the aggregation of α-synuclein, the protein whose misfolding and deposition is associated with Parkinsons disease. We identify a conformational change from the initially formed oligomers to stable, more compact proteinase-K-resistant oligomers as the key step that leads ultimately to fibril formation. The oligomers formed as a result of the structural conversion generate much higher levels of oxidative stress in rat primary neurons than do the oligomers formed initially, showing that they are more damaging to cells. The structural conversion is remarkably slow, indicating a high kinetic barrier for the conversion and suggesting that there is a significant period of time for the cellular protective machinery to operate and potentially for therapeutic intervention, prior to the onset of cellular damage. In the absence of added soluble protein, the assembly process is reversed and fibrils disaggregate to form stable oligomers, hence acting as a source of cytotoxic species.
PLOS ONE | 2008
Alison Wood-Kaczmar; Sonia Gandhi; Zhi Yao; Andrey Y. Abramov; Erik Miljan; Gregory Keen; Lee Stanyer; Iain Hargreaves; Kristina Klupsch; Emma Deas; Julian Downward; Louise Mansfield; Parmjit S. Jat; Joanne Taylor; Simon Heales; Michael R. Duchen; David S. Latchman; Sarah J. Tabrizi; Nicholas W. Wood
Parkinsons disease (PD) is a common age-related neurodegenerative disease and it is critical to develop models which recapitulate the pathogenic process including the effect of the ageing process. Although the pathogenesis of sporadic PD is unknown, the identification of the mendelian genetic factor PINK1 has provided new mechanistic insights. In order to investigate the role of PINK1 in Parkinsons disease, we studied PINK1 loss of function in human and primary mouse neurons. Using RNAi, we created stable PINK1 knockdown in human dopaminergic neurons differentiated from foetal ventral mesencephalon stem cells, as well as in an immortalised human neuroblastoma cell line. We sought to validate our findings in primary neurons derived from a transgenic PINK1 knockout mouse. For the first time we demonstrate an age dependent neurodegenerative phenotype in human and mouse neurons. PINK1 deficiency leads to reduced long-term viability in human neurons, which die via the mitochondrial apoptosis pathway. Human neurons lacking PINK1 demonstrate features of marked oxidative stress with widespread mitochondrial dysfunction and abnormal mitochondrial morphology. We report that PINK1 plays a neuroprotective role in the mitochondria of mammalian neurons, especially against stress such as staurosporine. In addition we provide evidence that cellular compensatory mechanisms such as mitochondrial biogenesis and upregulation of lysosomal degradation pathways occur in PINK1 deficiency. The phenotypic effects of PINK1 loss-of-function described here in mammalian neurons provides mechanistic insight into the age-related degeneration of nigral dopaminergic neurons seen in PD.
Human Molecular Genetics | 2011
Emma Deas; Helene Plun-Favreau; Sonia Gandhi; Howard Desmond; Svend Kjær; Samantha H. Y. Loh; Alan E. Renton; Robert J. Harvey; Alexander J. Whitworth; L. Miguel Martins; Andrey Y. Abramov; Nicholas W. Wood
Mutations in PTEN-induced kinase 1 (PINK1) cause early onset autosomal recessive Parkinsons disease (PD). PINK1 is a 63 kDa protein kinase, which exerts a neuroprotective function and is known to localize to mitochondria. Upon entry into the organelle, PINK1 is cleaved to produce a ∼53 kDa protein (ΔN-PINK1). In this paper, we show that PINK1 is cleaved between amino acids Ala-103 and Phe-104 to generate ΔN-PINK1. We demonstrate that a reduced ability to cleave PINK1, and the consequent accumulation of full-length protein, results in mitochondrial abnormalities reminiscent of those observed in PINK1 knockout cells, including disruption of the mitochondrial network and a reduction in mitochondrial mass. Notably, we assessed three N-terminal PD-associated PINK1 mutations located close to the cleavage site and, while these do not prevent PINK1 cleavage, they alter the ratio of full-length to ΔN-PINK1 protein in cells, resulting in an altered mitochondrial phenotype. Finally, we show that PINK1 interacts with the mitochondrial protease presenilin-associated rhomboid-like protein (PARL) and that loss of PARL results in aberrant PINK1 cleavage in mammalian cells. These combined results suggest that PINK1 cleavage is important for basal mitochondrial health and that PARL cleaves PINK1 to produce the ΔN-PINK1 fragment.
Annals of Neurology | 2006
Patrick M. Abou-Sleiman; Miratul M. K. Muqit; Neil Q. McDonald; Yan Xiang Yang; Sonia Gandhi; Daniel G. Healy; Kirsten Harvey; Robert J. Harvey; Emma Deas; Kailash P. Bhatia; Niall Quinn; Andrew J. Lees; David S. Latchman; Nicholas W. Wood
To investigate the significance of PINK1 mutations in sporadic Parkinsons disease (PD).
Journal of Neurochemistry | 2006
Miratul M. K. Muqit; Patrick M. Abou-Sleiman; Adrian T. Saurin; Kirsten Harvey; S Gandhi; Emma Deas; Simon Eaton; Martin Smith; Kerrie Venner; Antoni Matilla; Daniel G. Healy; William P. Gilks; Andrew J. Lees; Janice L. Holton; Tamas Revesz; Peter J. Parker; Robert J. Harvey; Nicholas W. Wood; David S. Latchman
Following our identification of PTEN‐induced putative kinase 1 (PINK1) gene mutations in PARK6‐linked Parkinsons disease (PD), we have recently reported that PINK1 protein localizes to Lewy bodies (LBs) in PD brains. We have used a cellular model system of LBs, namely induction of aggresomes, to determine how a mitochondrial protein, such as PINK1, can localize to aggregates. Using specific polyclonal antibodies, we firstly demonstrated that human PINK1 was cleaved and localized to mitochondria. We demonstrated that, on proteasome inhibition with MG‐132, PINK1 and other mitochondrial proteins localized to aggresomes. Ultrastructural studies revealed that the mechanism was linked to the recruitment of intact mitochondria to the aggresome. Fractionation studies of lysates showed that PINK1 cleavage was enhanced by proteasomal stress in vitro and correlated with increased expression of the processed PINK1 protein in PD brain. These observations provide valuable insights into the mechanisms of LB formation in PD that should lead to a better understanding of PD pathogenesis.
Biochimica et Biophysica Acta | 2011
Emma Deas; Nicholas W. Wood; Helene Plun-Favreau
The study of rare, inherited mutations underlying familial forms of Parkinsons disease has provided insight into the molecular mechanisms of disease pathogenesis. Mutations in these genes have been functionally linked to several key molecular pathways implicated in other neurodegenerative disorders, including mitochondrial dysfunction, protein accumulation and the autophagic-lysosomal pathway. In particular, the mitochondrial kinase PINK1 and the cytosolic E3 ubiquitin ligase parkin act in a common pathway to regulate mitochondrial function. In this review we discuss the recent evidence suggesting that the PINK1/parkin pathway also plays a critical role in the autophagic removal of damaged mitochondria–mitophagy. This article is part of a Special Issue entitled Mitochondria: the deadly organelle.
Proceedings of the National Academy of Sciences of the United States of America | 2015
Serene W. Chen; Srdja Drakulic; Emma Deas; Myriam M. Ouberai; Francesco A. Aprile; Rocío Arranz; Samuel Ness; Cintia Roodveldt; Tim Guilliams; Erwin de-Genst; David Klenerman; Nicholas W. Wood; Tuomas P. J. Knowles; Carlos Alfonso; Germán Rivas; Andrey Y. Abramov; José M. Valpuesta; Christopher M. Dobson; Nunilo Cremades
Significance Certain oligomeric species generated during the self-assembly of specific proteins into ordered fibrillar aggregates are likely to be key players in the initiation and spreading of neurodegenerative diseases. We have purified stable toxic oligomeric species of α-synuclein and defined and minimized their degree of heterogeneity, which has allowed us to identify distinct subgroups of oligomers and determine their structural properties and three-dimensional molecular architectures. All the oligomeric subgroups possess approximately cylindrical architectures with marked similarities to amyloid fibrils, suggesting that these types of oligomers are kinetically trapped during protein self-assembly. The relative stabilities and inherent pathological roles of different amyloid oligomers are likely to result from the multiplicity of pathways of the misfolding process and the remarkably slow rates of structural conversions. We describe the isolation and detailed structural characterization of stable toxic oligomers of α-synuclein that have accumulated during the process of amyloid formation. Our approach has allowed us to identify distinct subgroups of oligomers and to probe their molecular architectures by using cryo-electron microscopy (cryoEM) image reconstruction techniques. Although the oligomers exist in a range of sizes, with different extents and nature of β-sheet content and exposed hydrophobicity, they all possess a hollow cylindrical architecture with similarities to certain types of amyloid fibril, suggesting that the accumulation of at least some forms of amyloid oligomers is likely to be a consequence of very slow rates of rearrangement of their β-sheet structures. Our findings reveal the inherent multiplicity of the process of protein misfolding and the key role the β-sheet geometry acquired in the early stages of the self-assembly process plays in dictating the kinetic stability and the pathological nature of individual oligomeric species.